This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases, describes the Alta study, which investigated giroctocogene fitelparvovec gene therapy for severe hemophilia A. This condition is caused by a faulty factor 8 gene, leading to low factor 8 protein levels and excessive bleeding. The gene therapy delivers a working copy of the factor 8 gene to liver cells, helping them produce factor 8 and reduce bleeding episodes. The study assessed four different doses, and this summary presents results from the first two years of the five-year study.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study’ and was published in the Blood.

Visit Ash Publications using the link to read the original article.